Abvc Biopharma (ABVC) Long-Term Investments (2018 - 2026)

Abvc Biopharma (ABVC) has 9 years of Long-Term Investments data on file, last reported at $1.8 million in Q1 2026.

• Quarterly Long-Term Investments fell 33.13% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 33.13% YoY) and the FY2025 annual result came in at $1.9 million, down 16.84% from the prior year.
• Long-Term Investments eased to $1.8 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.8 million in Q2 2025 to a low of $816160.0 in Q3 2022.
• A 5-year average of $1.9 million and a median of $2.3 million in 2024 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments soared 228.05% — and 2026, when it tumbled 33.13%.
• Tracing ABVC's Long-Term Investments over 5 years: stood at $842070.0 in 2022, then surged by 200.18% to $2.5 million in 2023, then retreated by 10.64% to $2.3 million in 2024, then declined by 16.84% to $1.9 million in 2025, then retreated by 1.74% to $1.8 million in 2026.
• The last three Long-Term Investments figures came in at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.